http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
-
Emergent BioSolutions (EBS) to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
-
New Prospective Study Shows Significant Reduction In Reports Of Postoperative Halos From Patients Treated With TearScience LipiFlow Treatment Prior To Bilateral Cataract Surgery
-
Johnson & Johnson Vision Introduces VERITAS Vision System With Features To Address Key Unmet Needs In Cataract Surgery
-
Johnson & Johnson Vision Presents Scientific Data Validating Improved Surgical Outcomes With Latest Cataract Innovations And Legacy MGD Treatment At The 2021 ASCRS•ASOA Annual Meeting
-
Johnson & Johnson Vision Brings TECNIS Synergy And TECNIS Synergy Toric II PC-IOLS To North America For Cataract Patients
-
Johnson & Johnson Vision Expands "Sight For Kids" Program to Bring Eye Care to More Children and Unveils New "Vision for Good" Community Impact Report
-
Johnson & Johnson (JNJ) Vision Announces FDA Approval of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management
-
Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management
-
Johnson & Johnson Vision Announces The Approval Of TECNIS Synergy™ And TECNIS Synergy™ Toric II IOLs In The U.S. And TECNIS Synergy™ Toric II IOLs In Canada
-
Johnson & Johnson Vision Receives Approval in Canada for World's First and Only Drug-Releasing Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE® Theravision™ with Ketotifen
-
Emergent BioSolutions (EBS) committed to working with the FDA and Johnson & Johnson to quickly resolve issues
-
Johnson & Johnson Vision Introduces ACUVUE® Abiliti™ to Address the Growing Prevalence and Progression of Myopia in Children
-
Johnson & Johnson (JNJ) Vision Receives FDA Clearance and CE Mark for Next-Generation Phacoemulsification Machine, VERITAS Vision System
-
Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Next-Generation Phacoemulsification Machine, VERITAS™ Vision System
-
Johnson & Johnson Vision Announces Global Collaboration with Menicon to Bring Forward Contact Lenses to Help Manage the Progression of Myopia in Children
-
Emergent BioSolutions (EBS) On Track with Respect to COVID-19 Commitments; Receives Modified Task Order from U.S. to Support Opportunity for Further Expansion of Manufacturing Capacity for J&J (JNJ)
-
Johnson & Johnson Vision (JNJ) Receives Approval of World's First and Only Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE Theravision with Ketotifen
-
Johnson & Johnson Vision Receives Approval of World's First and Only Drug-Releasing Combination Contact Lens for Vision Correction and Allergic Eye Itch: ACUVUE® Theravision™ with Ketotifen
-
Johnson & Johnson Vision Introduces New ACUVUE® OASYS MULTIFOCAL with PUPIL OPTIMIZED DESIGN and Expands the ACUVUE® OASYS Portfolio of Offerings for Patients with Presbyopia
-
Merck (MRK) Confirms It Will Help Produce Johnson & Johnson’s (JNJ) COVID-19 Vaccine;
-
Johnson & Johnson Vision Celebrates 20 Years of Helping Cataract Patients with the See More Campaign and Global Patient Story Search
-
Nextech AR’s Virtual Event Platform Selected by Canadian Surgery Forum for Its 2021 Virtual Trade Show
-
Johnson & Johnson (JNJ) Vision Receives FDA Approval For Next Generation Monofocal Intraocular Lens For The Treatment Of Cataract Patients
-
Johnson & Johnson Vision Receives FDA Approval For Next Generation Monofocal Intraocular Lens - TECNIS Eyhance™ And TECNIS Eyhance™ Toric II IOLs - For The Treatment Of Cataract Patients
-
Legend Biotech (LEGN) Announces Initiation of Rolling Submission of BLA to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for Treatment of R/R Multiple Myeloma
-
Data from the ANDROMEDA Study Show Haematologic Response for DARZALEX®▼ (daratumumab) Subcutaneous Formulation Combination Regimen in Newly Diagnosed Light Chain (AL) Amyloidosis
-
New Survey Finds Critical Need for Education on Cataracts and Modern Treatment Options
-
Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
-
Biosense Webster Receives FDA Approval for THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation
-
New Survey on Eye Health Finds Most People Say They Know the Importance of an Annual Eye Exam, but - They Actually Don't and They're Not Getting One
-
Johnson & Johnson to pay more than $100 million to settle over 1,000 talc lawsuits: Bloomberg
-
Johnson & Johnson (JNJ) Completes Acquisition of Momenta Pharmaceuticals, Inc. (MNTA)
-
Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.
-
SpringWorks Therapeutics Inc. (SWTX) Announces Clinical Collaboration with Janssen (JNJ) to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myelo
-
Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
-
Biopharma Leaders Unite to Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite To Stand With Science
-
Biopharma Leaders Unite to Stand with Science
-
Biopharma Leaders Unite to Stand with Science
-
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
-
Johnson & Johnson (JNJ) Company, Actelion Pharmaceuticals Ltd, Presents TRITON Phase 3b Study
-
TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress
-
Arrowhead (ARWR), Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
-
Johnson & Johnson (JNJ) to Acquire Momenta Pharmaceuticals Inc. (MNTA) for $52.50/Share
-
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
-
Janssen (JNJ) Receives CHMP Positive Opinion for Expanded Use of IMBRUVICA in Combination with Rituximab for Previously Untreated Patients with CLL
-
Janssen Receives CHMP Positive Opinion for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
-
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®

